Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Monzon, Federico A ^a   Medeiros, Fabiola ^b   Lyons Weiler, Maureen ^a   Henner, W David ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAYO CLINIC   (United States)

^c Pathwork Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL; DNA MICROARRAY; EVALUATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MINNESOTA; NEOPLASMS, UNKNOWN PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PENNSYLVANIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 77149138310     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-3     Document Type: Article

References (42)

1. Diagnostic strategies for unknown primary cancer. GR Varadhachary JL Abbruzzese R Lenzi, Cancer 2004 100 1776 1785 10.1002/cncr.20202 15112256
2. Cancer of unknown primary site. FA Greco JD Hainsworth, Cancer: Principles & Practice of Oncology Philadelphia: Lippincott Williams & Wilkens, DeVita VT, Hellman S, Rosenberg SA, 7 2005 2213 2234
3. Carcinoma of unknown primary (CUP). N Pavlidis K Fizazi, Crit Rev Oncol Hematol 2009 69 271 278 10.1016/j.critrevonc.2008.09.005 18977667
4. National Cancer Institute, Carcinoma of Unknown Primary Treatment (PDQ®) Health Professional Version. http://www.cancer.gov/ Accessed Nov 11 2008
5. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
6. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. FA Greco HA Burris S Litchy JH Barton JE Bradof P Richards DC Scullin Jr JB Erland LH Morrissey JD Hainsworth, J Clin Oncol 2002 20 1651 1656 10.1200/JCO.20.6.1651 11896116 (Pubitemid 34260547)
7. Diagnostic and therapeutic management of cancer of an unknown primary. N Pavlidis E Briasoulis J Hainsworth FA Greco, Eur J Cancer 2003 39 1990 2005 10.1016/S0959-8049(03)00547-1 12957453 (Pubitemid 37297755)
8. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. JD Hainsworth DR Spigel C Farley DS Thompson DL Shipley FA Greco Minnie Pearl Cancer Research Network, J Clin Oncol 2007 25 1747 1752 10.1200/JCO.2006.09.3047 17470864
9. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. BJ Schneider B El-Rayes JH Muler PA Philip GP Kalemkerian KA Griffith MM Zalupski, Cancer 2007 110 770 775 10.1002/cncr.22857 17594717
10. Cancer of unknown primary origin: a decade of experience in a community-based hospital. JM Pimiento D Teso A Malkan SJ Dudrick JA Palesty, Am J Surg 2007 194 833 837 10.1016/j.amjsurg.2007.08.039 18005780
11. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. JL Abbruzzese MC Abbruzzese R Lenzi KR Hess MN Raber, J Clin Oncol 1995 13 2094 2103 7636553
12. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. GR Varadhachary MN Raber A Matamoros JL Abbruzzese, Lancet Oncol 2008 9 596 599 10.1016/S1470-2045(08)70151-7 18510991
13. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Occult Primary, v.1.2009. http://www.nccn.org/professionals/ physician-gls/PDF/occult.pdf
14. The importance of identifying CUP subsets. N Pavlidis Y Merrouche, Carcinoma of Unknown Primary Site New York, NY: Taylor & Francis Group, Fizazi K, 2006 37 48
15. Unknown primary tumors metastatic to liver. JP Ayoub KR Hess MC Abbruzzese R Lenzi MN Raber JL Abbruzzese, J Clin Oncol 1998 16 2105 2112 9626210
16. The advent of immunohistochemistry in carcinoma of unknown primary site: a major progress. JJ Voigt MC Mathieu F Bibeau, Carcinoma of Unknown Primary Site New York, NY: Taylor & Francis Group, Fizazi K, 2006 25 35
17. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. RW Brown LB Campagna JK Dunn PT Cagle, Am J Clin Pathol 1997 107 12 19 8980361
18. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. JL Dennis TR Hvidsten EC Wit J Komorowski AK Bell I Downie J Mooney C Verbeke C Bellamy WN Keith KA Oien, Clin Cancer Res 2005 11 3766 3772 10.1158/1078-0432.CCR-04-2236 15897574
19. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. SY Park BH Kim JH Kim S Lee GH Kang, Arch Pathol Lab Med 2007 131 1561 1567 17922593
20. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. DV Schapira AR Jarrett, Arch Intern Med 1995 155 2050 2054 10.1001/archinte.155.19.2050 7575063
21. Multiclass cancer diagnosis using tumor gene expression signatures. S Ramaswamy P Tamayo R Rifkin S Mukherjee CH Yeang M Angelo C Ladd M Reich E Latulippe JP Mesirov T Poggio W Gerald M Loda ES Lander TR Golub, Proc Natl Acad Sci USA 2001 98 15149 15154 10.1073/pnas.211566398 11742071
22. Molecular classification of human carcinomas by use of gene expression signatures. AI Su JB Welsh LM Sapinoso SG Kern P Dimitrov H Lapp PG Schultz SM Powell CA Moskaluk HF Frierson Jr GM Hampton, Cancer Res 2001 61 7388 7393 11606367
23. Identifying tumor origin using a gene expression-based classification map. P Buckhaults Z Zhang YC Chen TL Wang B St Croix S Saha A Bardelli PJ Morin K Polyak RH Hruban VE Velculescu IeM Shih, Cancer Res 2003 63 4144 4149 12874019
24. Multi-platform, multi-site, microarray-based human tumor classification. G Bloom IV Yang D Boulware KY Kwong D Coppola S Eschrich J Quackenbush TJ Yeatman, Am J Pathol 2004 164 9 16 14695313
25. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. RW Tothill A Kowalczyk D Rischin A Bousioutas I Haviv RK van Laar PM Waring J Zalcberg R Ward AV Biankin RL Sutherland SM Henshall K Fong JR Pollack DD Bowtell AJ Holloway, Cancer Res 2005 65 4031 4040 10.1158/0008-5472.CAN-04-3617 15899792
26. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. D Talantov J Baden T Jatkoe K Hahn J Yu Y Rajpurohit Y Jiang C Choi JS Ross D Atkins Y Wang A Mazumder, J Mol Diagn 2006 8 320 329 10.2353/jmoldx.2006.050136 16825504
27. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. XJ Ma R Patel X Wang R Salunga J Murage R Desai JT Tuggle W Wang S Chu K Stecker R Raja H Robin M Moore D Baunoch D Sgroi M Erlander, Arch Pathol Lab Med 2006 130 465 473 16594740
28. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. CI Dumur M Lyons-Weiler C Sciulli CT Garrett I Schrijver TK Holley J Rodriguez-Paris JR Pollack JL Zehnder M Price JM Hagenkord CT Rigl LJ Buturovic GG Anderson FA Monzon, J Mol Diagn 2008 10 67 77 10.2353/jmoldx.2008.070099 18083688
29. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. FA Monzon M Lyons-Weiler LJ Buturovic CT Rigl WD Henner C Sciulli CI Dumur F Medeiros GG Anderson, J Clin Oncol 2009 27 2503 2508 10.1200/JCO.2008.17.9762 19332734
30. MicroRNAs accurately identify cancer tissue origin. N Rosenfeld R Aharonov E Meiri S Rosenwald Y Spector M Zepeniuk H Benjamin N Shabes S Tabak A Levy D Lebanony Y Goren E Silberschein N Targan A Ben-Ari S Gilad N Sion-Vardy A Tobar M Feinmesser O Kharenko O Nativ D Nass M Perelman A Yosepovich B Shalmon S Polak-Charcon E Fridman A Avniel I Bentwich Z Bentwich D Cohen A Chajut I Barshack, Nat Biotechnol 2008 26 462 469 10.1038/nbt1392 18362881
31. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. J Bridgewater R van Laar A Floore L Van'T Veer, Br J Cancer 2008 98 1425 1430 10.1038/sj.bjc.6604315 18414470
32. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. HM Horlings RK van Laar JM Kerst HH Helgason J Wesseling JJ van der Hoeven MO Warmoes A Floore A Witteveen J Lahti-Domenici AM Glas LJ Van't Veer D de Jong, J Clin Oncol 2008 26 4435 4441 10.1200/JCO.2007.14.6969 18802156
33. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. GR Varadhachary D Talantov MN Raber C Meng KR Hess T Jatkoe R Lenzi DR Spigel Y Wang FA Greco JL Abbruzzese JD Hainsworth, J Clin Oncol 2008 26 4442 4428 10.1200/JCO.2007.14.4378 18802157
34. Gene expression data analytics with interlaboratory validation for identifying anatomical sites of origin of metastatic carcinomas. J Moraleda N Grove Q Tran, J Clin Oncol 2004 22 July 15 suppl bstr 9625
35. Comparative study of primary mammary small cell carcinoma, carcinoma with endocrine features and invasive ductal carcinoma. J Yamamoto K Ohshima K Nabeshima S Ikeda H Iwasaki M Kikuchi, Oncol Rep 2004 11 825 831 15010880
36. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. E Compérat F Zhang C Perrotin T Molina P Magdeleinat B Marmey JF Régnard J Audouin S Camilleri-Brot, Mod Pathol 2005 18 1371 1376 10.1038/modpathol.3800422 15861215
37. Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. F Medeiros CT Rigl GG Anderson SH Becker KC Halling, Arch Pathol Lab Med 2007 131 1805 1816 18081440
38. Raising the profile of cancer of unknown primary. KA Oien TR Evans, J Clin Oncol 2008 26 4373 4375 10.1200/JCO.2008.17.6156 18802148
39. Male breast cancer in the veterans affairs population: a comparative analysis. ZA Nahleh R Srikantiah M Safa AR Jazieh A Muhleman R Komrokji, Cancer 2007 109 1471 1477 10.1002/cncr.22589 17342768
40. Synchronous bilateral invasive lobular breast cancer presenting as carcinomatosis in a male. JT Spencer J Shutter, Am J Surg Pathol 2009 33 470 474 10.1097/PAS.0b013e318190d10d 19092630
41. Cancer of unknown primary site: missing primary or missing biology? G Pentheroudakis E Briasoulis N Pavlidis, The Oncologist 2007 12 418 425 10.1634/theoncologist.12-4-418 17470684 (Pubitemid 46698719)
42. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. G Pentheroudakis FA Greco N Pavlidis, Cancer Treat Rev 2009 35 221 227 10.1016/j.ctrv.2008.10.003 19046817